Eli Lilly and Company (NYSE:LLY) Releases FY 2026 Earnings Guidance

Eli Lilly and Company (NYSE:LLY) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 35.500-36.500 for the period, compared to the consensus EPS estimate of 36.120. The company issued revenue guidance of $85.0 billion-$87.0 billion, compared to the consensus revenue estimate of $85.4 billion.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Truist Financial raised their price target on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Guggenheim boosted their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Finally, Wolfe Research reissued an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Price Performance

LLY opened at $1,170.78 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 41.59, a P/E/G ratio of 1.39 and a beta of 0.51. The firm’s fifty day moving average price is $1,154.75 and its two-hundred day moving average price is $1,044.52.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.06 by $2.32. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.69 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 34.91 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 results: Revenue rose 48% year over year to approximately $23.0 billion, driven primarily by higher volume for diabetes drug Mounjaro and obesity treatment Zepbound. Non-GAAP EPS was $8.38, well above the $6.06 analyst consensus; reported EPS was $7.94. Lilly second-quarter 2026 financial results
• Positive Sentiment: Higher revenue guidance: Lilly now expects 2026 revenue of $85 billion to $87 billion, up from its previous $82 billion to $85 billion forecast and broadly in line with estimates. Full-year adjusted EPS guidance was set at $35.50 to $36.50, near the $36.12 consensus. Reuters revenue forecast report
• Positive Sentiment: GLP-1 momentum remains the key catalyst: Continued demand for Mounjaro and Zepbound is fueling revenue growth and supporting investor confidence in Lilly’s obesity and diabetes franchise. CNBC Lilly earnings report
• Positive Sentiment: Pipeline progress: Lilly will expand limited early access to experimental obesity drug retatrutide before potential U.S. approval. Separately, the FDA granted breakthrough therapy designation to cancer drug candidate olomorasib for pancreatic cancer, while Lilly and Amplia agreed to study olomorasib in combination with narmafotinib for lung cancer.
• Positive Sentiment: Commercial partnership: CVS Health is revamping its weight-management program through a partnership with Lilly, potentially broadening access to the company’s GLP-1 therapies. CVS Health Lilly partnership

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mcguire Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $38,000. Gilpin Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth $54,000. Turning Point Benefit Group Inc. bought a new position in shares of Eli Lilly and Company in the third quarter worth $56,000. Vermillion & White Wealth Management Group LLC raised its stake in shares of Eli Lilly and Company by 57.1% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 55 shares of the company’s stock valued at $59,000 after purchasing an additional 20 shares during the period. Finally, Graney & King LLC raised its stake in shares of Eli Lilly and Company by 14.6% during the 2nd quarter. Graney & King LLC now owns 181 shares of the company’s stock valued at $141,000 after purchasing an additional 23 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.